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Purpose: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab
0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort.
Patients and Methods: This Belgian (BE) cohort of the 5-year global observational
LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity
(VA), central retinal thickness (CRT) and safety.
Results: The mean age was 79.5±7.7 years. The majority of patients (67.7%) were female
and all patients were Caucasian. Most patients previously received ranibizumab with only
17.5% of patients being treatment-naïve. The injection frequency declined over time irre-
spective of prior treatment status (p<0.0001), with treatment-naïve eyes receiving a mean of
4.2±2.9 yearly injections and prior-ranibizumab eyes 3.6±2.7. Regression analysis confirmed
first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of
−1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were
statistically non-significant (p=0.90) but declined slightly after year one (p<0.0001).
Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline
(p<0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new
safety findings were identified.
Conclusion: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of rani-
bizumab for nAMD treatment. The observed low injection frequency reflects a need for more
rigorous treatment in real-world settings.
Clinical Trial Registration: NCT01318941.
Keywords: ranibizumab, effectiveness, safety, treatment patterns, neovascular age-related
macular degeneration, Belgium
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in
patients over the age of 50 in developed countries.1–7 The neovascular form of
the disease (nAMD) is characterized by the abnormal growth of choroidal blood
vessels beneath the macula that disrupts the anatomy and function of the neurosen-
sory retina and causes severe and irreversible loss of vision.8–10
Ranibizumab (Lucentis®, Novartis, Basel, Switzerland and Genentech Inc., South
San Francisco, CA, USA), a recombinant, humanized monoclonal antibody fragment
that neutralizes all active forms of vascular endothelial growth factor A (VEGF-A), has
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been approved as intravitreal therapy for several retinal dis-
eases, including nAMD (approved in 2006 in the US and in
2007 in Europe). While the efficacy and safety profile of
ranibizumab use in nAMD is well established based on
clinical trial evidence,9–12 most evaluations of the longer-
term (≥2 years) effectiveness and safety of ranibizumab in
routine clinical practice have been limited-sample studies in
one or a few countries.13–19 In addition, treatment patterns of
ranibizumab have not been extensively investigated in a real-
world setting.
In order to provide an answer to these remaining ques-
tions, the LUMINOUSTM study, a 5-year, global, multicen-
ter, observational, open-label study that evaluated real-world
ranibizumab use and associated outcomes in diverse popula-
tions, settings, and clinical practices for any approved indica-
tion included in the local product label, was conducted.
Being the largest prospective observational trial in the med-
ical retina field, this study recruited 30,138 patients from 488
sites in 42 countries.20
We have previously reported on the 2-year13 and 6-
year14 outcomes of treatment with ranibizumab for nAMD
as observed in routine clinical practice in Belgium. Here,
we assessed treatment patterns and associated outcomes in
patients with nAMD of the Belgian (BE) cohort from the
global LUMINOUS study, thus adding to the evidence
base of real-world effectiveness and safety of ranibizumab
use in Belgium.
Materials and Methods
Design, Sample and Setting
This analysis includes the Belgian nAMD subsample of
the global, prospective, multicenter, observational, non-
interventional, open-label, single-arm LUMINOUS study
(NCT01318941). This 5-year study (March 2011-April
2016) recruited 30,138 consenting adults patients (≥18
years), enrolled by the local investigators at the participat-
ing outpatient clinics. Patients were previously treated
with, currently treated with, or initiating treatment with
ranibizumab for all approved indications per the local
product label.20
The global sample included 22,717 patients with
nAMD. The LUMINOUS methodology has been detailed
elsewhere.20 We summarize below key elements relevant
to the LUMINOUS-BE analysis.
Being an observational study, all data were recorded as
available from routine clinical practice on a clinical visit
schedule determined by the treating physician. Patients not
seen at least once per year were discontinued from the
study. The overall duration of the study was 5 years, with a
minimum of 1-year follow-up period per patient.
The primary eye with nAMD was the unit of observa-
tion and analyses were stratified by prior treatment status.
Excluded were patients receiving systemic or ocular anti-
VEGF therapy other than ranibizumab in the 90 or 30 days
prior to enrollment, respectively, or participating in other
investigational studies.
Variables and Measurement
Baseline data included socio-demographics, (non-)ocular
medical history, prior (non-)ocular treatments, best-cor-
rected visual acuity (VA), central retinal thickness (CRT),
and start date and dose of ranibizumab therapy. The lesion
characteristics were identified by the investigator and cap-
tured at start of study. Follow-up data included the admin-
istration date of ranibizumab, concomitant (non-)ocular
treatments, (serious) adverse events (SAE/AE), reasons
for discontinuation, VA, and CRT. The number of ranibi-
zumab 0.5 mg injections was calculated per completed
year of follow-up. Safety evaluations comprised the mon-
itoring and assessment of occurrence, relationship, and
severity of (non-)ocular AEs.
Effectiveness parameters used for long-term evaluation
were: 1) change in best-corrected VA since baseline,
expressed in (approximate) Early Treatment Diabetic
Retinopathy Study (ETDRS) letters, and 2) change in
CRT since baseline, expressed in µm. VA change was
also categorized as gains of ≥15, 10–14, or 5–9 letters
and VA status as the proportion of eyes with VA of ≥73
letters.
Statistical Analysis
Patient demographics, medical history, ocular disease his-
tory, prior treatments, and other baseline characteristics
were presented using standard descriptive statistics under
consideration of applicable levels of measurement.
We applied linear mixed regression analysis, employ-
ing random intercepts to separate out within-center from
between-center and within-patient from between-patient
variability. Evaluation of changes over time among the
prior treatment subgroups was achieved by entering an
interaction of subgroup and time variables and specifying
contrasts for specific hypotheses testing. The level of
statistical significance was set at 0.05. All statistical ana-
lyses were performed using SAS® v.9.4 (SAS Institute
Inc., Cary, NC, USA).
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LUMINOUS was designed, implemented, and reported
in accordance with the Guidelines for Good
Pharmacoepidemiology Practices issued by the International
Society for Pharmacoepidemiology, with any applicable
national guidelines, and with the ethical principles laid down
in the Declaration of Helsinki. Approval was obtained from an
Ethics Committee or Institutional Review Board at each parti-
cipating center and all patients or their legal proxy gavewritten
informed consent.
Results
Sample Composition & Baseline Ocular
Characteristics
Thirteen Belgian centers enrolled 229 patients with
nAMD, with a mean age of 79.5±7.7 years (Table 1).
The majority of patients (67.7%) were female, and all
patients were Caucasian.
Mean follow-up time was 30.5±17.0 months, with half
the patients discontinuing the study early (n=114; 49.8%)
at an average of 13.6±13.4 months. Sample sizes at 1, 2, 3
and 4 years were 186 (81.2%), 139 (60.7%), 100 (43.7%)
and 48 (21.0%), respectively. Primary reasons for prema-
ture study stop were loss to follow up (37.7%) or switch to
another anti-VEGF agent (24.6%) (Table 1). The most
frequent non-ocular comorbidities were hypertension
(n=119, 52.0%) and hypercholesterolemia/hyperlipidemia
(n=107, 46.7%). With regard to the lesion characteristics,
as captured at start of study by the investigators, about
20% (n=46) of patients had a lesion of the predominantly
classic type and 86 (37.6%) patients had a pigment epithe-
lium detachment. In total, 40 (17.5%) patients were treat-
ment-naïve and the remaining 189 (82.5%) had been
previously treated with ranibizumab (prior-ranibizumab).
At baseline, the mean VA was higher in patients treated
previously with ranibizumab (63.5±13.6 letters) compared
with treatment-naïve patients (59.6±15.8 letters). The mean
baseline CRT, on the other hand, was lower in patients treated
previously with ranibizumab (279.8±88.7 µm) compared
with treatment-naïve patients (341.2±92.0 µm).
Treatment Patterns
The mean number of yearly visits was 7.9±2.8 for treatment-
naïve and 7.5±2.9 for prior-ranibizumab patients (Table 2).
Regarding the mean number of yearly injections, treat-
ment-naïve eyes received 4.2±2.9 yearly injections and
Table 1 Patient Demographic and Clinical Characteristics at
Study Entry, Study Discontinuation (N=229)
Parameters Value
Age: median, mean±SD (n) 80.0, 79.5±7.7 (223)




History of coronary artery disease 28 (12.2)
Diabetes 19 (8.3)
Obesity 18 (7.9)
Myocardial infarction 14 (6.1)
Stroke 13 (5.7)
Other thromboembolic event 15 (6.6)
Secondary eyes treated: n (%) 53 (23.1)
Ocular historya: n (%)
Pigment epithelium detachment 86 (37.6)
Lesion type: Predominantly classic 46 (20.1)
Lesion size (> 1 DA) 151 (65.9)
Choroidal neovascularization 216 (94.3)
Retinal angiomatous proliferation 20 (8.7)
Prior treatments: n (%)
None (treatment-naïve) 40 (17.5)
Prior treatment (including ranibizumab) 189 (82.5)
Other prior treatments (not including
ranibizumab)
0 (0.0)
Time (months) since diagnosis: median, mean±SD (n)
All patients 15.0, 28.3±37.1 (229)
Treatment-naïve eyes 0.0, 6.9±22.4 (40)
Prior ranibizumab 21.0, 32.8±38.0 (189)
Ophthalmological parameters: median, mean±SD (n)
Visual acuity (ETDRS letters)
All patients 65.0, 62.9±14.0 (223)
Treatment-naïve 60.0, 59.6±15.8 (37)
Prior ranibizumab 65.0, 63.5±13.6 (186)
Central retinal thickness (µm)
All patients 275.0, 290.3±92.0 (223)
Treatment-naïve 324.0, 341.2±92.0 (38)
Prior ranibizumab 266.0, 279.8±88.7 (185)
Study discontinuation: n (%) 114 (49.8)
Lost to follow-up 43 (37.7)b
Switch to other anti-VEGF agent 28 (24.6)b
Death 18 (15.8)b
Subject withdrawal 8 (7.0)b
Unsatisfactory therapeutic event 5 (4.4)b
Protocol deviation 4 (3.5)b
Adverse event 4 (3.5)b
Study drug no longer needed 2 (1.8)b
Administrative problems 2 (1.8)b
Notes: aCategories not mutually exclusive; b% of patients who discontinued the
study (n=114).
Abbreviations: DA, disc area; ETDRS, Early Treatment Diabetic Retinopathy
Study; SD, standard deviation; VEGF, vascular endothelial growth factor; µm,
micrometer.
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eyes previously treated with ranibizumab 3.6±2.7, with an
injection frequency declining over time irrespective of
prior treatment status (p<0.0001). With the decline in
frequency, an increase in time intervals between injections
was observed (Table S1).
Besides unstable VA, the most common reason for re-
treatment was optical coherence tomography abnormalities
at 62.3% and 63.9% of re-treatments in treatment-naïve
and prior-ranibizumab cohorts, respectively (Table S2).
Visual Acuity
Quarterly changes in letters read compared to baseline for
treatment-naïve and prior-ranibizumab eyes are presented
in Figure 1 (see Table S3 for point estimates). For treat-
ment-naïve eyes, regression analysis confirmed first-year
increases with annual VA change estimates of β=3.9 (95%
CI: 1.5, 6.3; p=0.002; Table S4). After the first year, VA
decreased slightly by −1.8 letters per year (β= −1.8; 95%
CI: −2.9, −0.7; p=0.001). For prior-ranibizumab-treated
eyes, changes over 1 year were statistically non-significant
at 0.03±11.7 (β=−0.1; 95% CI: −1.2, 1.1; p=0.90). After
1 year, VA declined slightly in prior-ranibizumab eyes
(β= −1.7; 95% CI: −2.2, −1.2; p<0.0001).
Across years 1 through 4, between 33.3% and 53.3% of
treatment-naïve eyes and between 30.4% and 36.3% of prior-
ranibizumab eyes attained ≥73 letters read (Table S5). Gains
of at least 5 letters (ie, sum of eyes with ≥5, ≥10, and ≥15
letters gained) ranged from 47.6% to 66.7% for treatment-
naïve and from 32.9% to 39.5% for prior-ranibizumab over
all 4 years.
Central Retinal Thickness
Quarterly changes in CRT compared to baseline for treat-
ment-naïve and prior-ranibizumab eyes are depicted in
Figure 2 (see Table S3 for point estimates). Regression
analysis (Table S4) showed that the CRT of treatment-
naïve eyes decreased over time at a rate of −14.0 µm per
year from baseline (95% CI: −18.6, −9.4; p<0.0001),
whereas prior-ranibizumab eyes remained stable (β=−0.8,
95% CI: −2.7, 1.1, p=0.43).
Safety
Ocular AEs were reported in 64 (27.9%) patients (treat-
ment-naïve: 22 [55.0%], prior-ranibizumab: 42 [22.2%])
(Table S6). Non-ocular AEs were reported in 100 (43.7%)
patients (treatment-naïve: 17 [42.5%], prior-ranibizumab:
83 [43.9%]) (Table S6). Ocular adverse events suspected
to be treatment-related (ranibizumab and/or ocular injec-
tion) were reported for 14 (6.1%) patients (treatment-
naïve: 5 [12.5%], prior-ranibizumab: 9 [4.8%]), the most
common of which were conjunctival haemorrhage,
endophthalmitis, and eye pain (Table S7). Five (2.6%)
prior-ranibizumab patients experienced seven non-ocular
AEs suspected to be related to ranibizumab and/or ocular
injection (Table S7). Eleven (4.8%) patients had ocular
SAEs, leading to discontinuation of ranibizumab for
3 patients (1.3%); however, only two (0.9%) were sus-
pected to be treatment related. Sixty (26.2%) patients
experienced non-ocular SAEs, six (2.6%) of which were
suspected to be treatment related but did not result in
treatment discontinuation. An additional four patients had
ocular and two had non-ocular AEs (all non-serious) lead-
ing to discontinuation. There were 18 deaths (7.9%) during
the study period, none of which were suspected to be
treatment-related.











455 7.0, 7.6±2.9 4.0, 3.7±2.7
Year 1 184 8.0, 7.9±2.6 4.0, 4.4±2.7
Year 2 133 7.0, 7.1±2.4 3.0, 3.5±2.7
Year 3 97 7.0, 7.4±3.1 3.0, 2.8±2.4
Year 4 41 8.0, 8.7±4.1 4.0, 3.2±2.8





75 8.0, 7.9±2.8 4.0, 4.2±2.9
Year 1 35 8.0, 8.4±3.1 5.0, 5.3±3.0
Year 2 21 7.0, 7.3±2.1 3.0, 3.8±2.5
Year 3 14 7.5, 8.0±3.0 2.5, 2.8±2.2
Year 4 5 7.0, 7.4±3.0 1.0, 2.4±2.5





380 7.0, 7.5±2.9 4.0, 3.6±2.7
Year 1 149 7.0, 7.7±2.5 4.0, 4.2±2.6
Year 2 112 7.0, 7.1±2.5 3.0, 3.4±2.8
Year 3 83 7.0, 7.3±3.1 3.0, 2.8±2.5
Year 4 36 8.0, 8.8±4.2 4.0, 3.3±2.8
Notes: an=number of visits/treatments for eyes up to their last completed year.
Abbreviation: SD, standard deviation.
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Figure 1 Mean VA change (in ETDRS letters ± standard errors) from baseline per quarter.
Notes: Pre-treatment status category of the eye: Treatment-naïve= ; Prior ranibizumab = . Baseline n (month 0)=number of patients; all other n=number
of measurements within the quarter (multiple assessments per patient possible).
Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.
Figure 2 Mean CRT change (in µm ± standard errors) from baseline per quarter.
Notes: Pre-treatment status category of the eye: Treatment-naïve= ; Prior ranibizumab = . Baseline n (month 0)=number of patients; all other n=number
of measurements within the quarter (multiple assessments per patient possible).
Abbreviations: CRT, central retinal thickness; µm, micrometer.
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This analysis of the Belgian patients with nAMD in the
real-world LUMINOUS study consisted of 229 treatment-
naïve or prior-ranibizumab-treated patients with an aver-
age follow-up of 2.5 years.
The outcomes for the treatment-naïve eyes were lar-
gely consistent with data from previous longer-term real-
world studies of ranibizumab,13–19 including two Belgian
studies reporting on 2-year and 6-year outcomes.13,14
Although variability was detected in the VA and CRT
values, overall, a generally well-preserved mean VA was
observed, with an initial gain that was gradually lost over
time (−1.8 letters/year). Anatomically, a sustained
decrease in mean CRT was recorded to study end. This
discrepancy in long-term visual and anatomic results is
consistent with prior findings.14,18,21 Similarly, the prior-
ranibizumab eyes showed a slight decline (−1.7 letters/
year) in VA from year 1 onwards, but stable CRT through-
out the study period. Reasonably, though pre-ranibizumab
VA and CRT parameters were not available for the pre-
viously ranibizumab-treated eyes, (many of) these eyes
had probably already achieved a therapeutic benefit by
the start of the LUMINOUS study and entered the study
with stable disease.
Of note, the VA and CRT outcomes observed in this
study were associated with a rather low mean number of
yearly injections and a steadily declining injection fre-
quency over time. Several studies have reported a relation-
ship between anti-VEGF treatment frequency and VA
outcomes.13,18,19,22–25 For instance, in SEVEN-UP,25 a
multicenter, non-interventional cohort study of 65 patients
originally treated with ranibizumab in the ANCHOR and
MARINA trials and the HORIZON extension, showed that
better visual outcomes were obtained among intensively
treated patients, suggesting an association with injection
frequency. One retrospective study18 evaluating an as-
needed ranibizumab regimen over 5 years also found a
positive association between number of injections and
improvements in VA, suggesting the benefit of regular
treatment beyond the initial phase. The retrospective
AURA study19 demonstrated that more frequent visits
(ie, monitoring) and injections (ie, re-treatments) were
associated with maintenance of VA gains.
The PRN dosing schedule with treatment guidance by
VA and/or optical coherence tomography was the regimen
of choice in Belgium during the LUMINOUS study. In
individualized, reactive, as-needed anti-VEGF regimens,
monitoring frequency and re-treatment criteria impact
effectiveness.12,26-28 Being a chronic, progressive disease,
nAMD requires sustained monitoring and treatment for
many years.15,16,25 However, (re-)treatment inertia may be
responsible for irreversible VA deterioration;29 thus, PRN
regimens should include monthly monitoring in order to
treat any recurrence as soon as possible prior to lasting
VA damage. A recent secondary analysis of the
Comparison of Age-Related Macular Degeneration
Treatment Trial, a randomized clinical trial, has shown
that visit adherence contributes to visual acuity outcomes.30
In the current analysis, the mean number of yearly visits
was 7.6±2.9, which is not as strict as the monthly monitor-
ing in clinical trials and reflects the contingencies of real-
life situations, such as practical feasibility and patients’
willingness and ability to comply. Indeed, in the setting of
routine clinical practice, where patients are not followed as
intensively as in clinical trials nor treated in accordance
with a study protocol, the undertreatment may be accom-
panied by multiple recurrences of pronounced exudation,
potentially damaging photoreceptors and thus leading to
vision loss.29,31 This may explain the functional deteriora-
tion noticed in this Belgian analysis despite morphologic
response to therapy.
Since nAMD patients often require anti-VEGF treat-
ment for many years, evaluation of the long-term ocular
and non-ocular safety is necessary. Overall, the ocular and
non-ocular AEs observed in the Belgian nAMD sample of
the LUMINOUS study were consistent with the types of
AEs observed in prior controlled studies and consistent
with the well-established safety profile of ranibizumab. No
new safety findings were identified.
Limitations of this LUMINOUS-BE analysis are
similar to those of the parent global LUMINOUS study.
First, due to convenience sampling, selection bias cannot
be excluded. Furthermore, as this was a study on real-
world ranibizumab practice patterns and outcomes, all
patients were treated with ranibizumab and there was no
comparison group of untreated patients or patients trea-
ted only with other therapies. Lastly, as described in
other long-term real-world studies,16,32,33 the study dis-
continuation rate was significant in the current analysis
with half of the patients stopping the study prematurely.
Although the data reflect the long-term patient journey in
real-life practice, the dropout rate in combination with
the rather small sample size may affect the reliability of
the effectiveness results, primarily beyond the first year.
In analogy with the 2-year Belgian HELIOS study,13
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lost-to-follow-up was the main cause for patient drop-out
in the current analysis. Recently a study highlighted the
significant visual acuity decline observed after a period
of being lost to follow-up.34 Factors related to poor
follow-up adherence have been identified in previous
studies and include among others older age, greater dis-
tance to hospital, and lower baseline vision.16,32,35
Though loss of patients from regular follow-up in the
long-term is inevitable, these findings highlight the
importance of identifying patients at risk and exploring
measures to improve proper therapy adherence in order
to avoid the deleterious effects caused by a gap in care.
Notwithstanding these limitations and bearing in mind
the natural evolution of the disease, the current Belgian
sample of the LUMINOUS reconfirms the well-character-
ized benefit-risk profile of ranibizumab for treatment of
nAMD in a real-world clinical setting and adds to the
growing body of evidence of the long-term real-world
effectiveness and safety of ranibizumab. The observed
low injection frequency reflects a need for more rigorous
treatment in real-world settings. As such, the real-world
evidence from this study may help guide Belgian clini-
cians in optimizing the frequency of ranibizumab injec-
tions in the management of nAMD and counseling patients
undergoing long-term anti-VEGF therapy in clinical
practice.
Conclusions
LUMINOUS-BE reports long-term real-world ranibizu-
mab treatment patterns and clinical outcomes in nAMD
patients that supports the well-characterized benefit-risk
profile of ranibizumab. A PRN dosing schedule prevailed
in Belgium at the time and a pattern of relative under-
treatment was observed, consistent with other real-world
studies utilizing this approach.
Abbreviations
AE, adverse event; CRT, central retinal thickness; ETDRS,
Early Treatment Diabetic Retinopathy Study; nAMD, neo-
vascular (wet) age-related macular degeneration; SAE,
serious adverse event; VA, visual acuity; VEGF, vascular
endothelial growth factor.
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